Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
In this issue...
Drug safety advice
- Methylphenidate: updated guidance on safe and effective use in ADHD
- Atomoxetine: risk of psychotic or manic symptoms
- Antipsychotics: use in elderly patients with dementia
- Exenatide (Byetta): risk of severe pancreatitis and renal failure
- Bisphosphonates: atypical stress fractures
Yellow Card scheme update
- Adverse drug reactions in focus: progressive multifocal leukoencephalopathy
Hot topic
- Public perception of herbal medicines
Stop press
- Efalizumab (Raptiva): recommendation to suspend marketing authorisation
- Patient-controlled analgesia extension sets: risk of inadequate pain relief
- Effects of MRI on implantable drug pumps
- Oral bowel cleansing solutions: risk of harm
Other information from the MHRA
- Patient Information Leaflets of the month: smoking-cessation aids
- Consultation: changes to legislation and working during an influenza pandemic
Drug Safety Update: Volume 2 Issue 8, March 2009 
